A
Anila Dwivedi
Researcher at Central Drug Research Institute
Publications - 60
Citations - 1192
Anila Dwivedi is an academic researcher from Central Drug Research Institute. The author has contributed to research in topics: Estrogen receptor & Apoptosis. The author has an hindex of 19, co-authored 60 publications receiving 972 citations. Previous affiliations of Anila Dwivedi include Council of Scientific and Industrial Research & Academy of Scientific and Innovative Research.
Papers
More filters
Journal ArticleDOI
Therapeutic options for management of endometrial hyperplasia
TL;DR: Novel therapeutic agents precisely targeting the inhibition of estrogen receptor, growth factor receptors, and signal transduction pathways are likely to constitute an optimal approach for treatment of EH.
Journal ArticleDOI
ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
Ruchi Saxena,Anila Dwivedi +1 more
TL;DR: The mechanism of action, preclinical and clinical trial data of the agents that are in use for targeting the EGFR/HER‐2 pathway and the current status and the future clinical trial promises of these agents have been pondered to provide better and more efficacious treatment strategies for breast cancer patients.
Journal ArticleDOI
(-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation.
TL;DR: EGCG inhibits cellular proliferation via inhibiting ERK activation and inducing apoptosis via ROS generation and p38 activation in endometrial carcinoma cells, which suggest that EGCG reduces the glutathione levels, which might be responsible for enhanced ROS generation causing oxidative stress inendometrial cancer cells.
Journal ArticleDOI
Synthesis and biological evaluation of 3,4,6-triaryl-2-pyranones as a potential new class of anti-breast cancer agents.
Ravi Shankar,Bandana Chakravarti,Uma S. Singh,Mohd. Imran Ansari,Shreekant Deshpande,Shailendra Kumar Dhar Dwivedi,Hemant K. Bid,Rituraj Konwar,Geetika Kharkwal,Vishal Chandra,Anila Dwivedi,Kanchan Hajela +11 more
TL;DR: A series of 3,4,6-triaryl-2-pyranones, new class of anti-breast cancer agents, have been synthesized as a structural variants of cyclic triphenylethylenes by replacing the fused benzene ring with pendant phenyl ring to mimic the phenolic A ring of estradiol.
Journal ArticleDOI
Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents
Atul Kumar,Atul Kumar,Garima Gupta,Ajay Kumar Bishnoi,Ajay Kumar Bishnoi,Ruchi Saxena,Karan Singh Saini,Rituraj Konwar,Sandeep Kumar,Anila Dwivedi,Anila Dwivedi +10 more
TL;DR: The design and synthesis of bioisosteres of spirooxindole (MI-63/219), a small-molecule inhibitors of the MDM2-p53 interaction as anti-breast cancer agents restores the p53 function, which triggers molecular events consistent with cell cycle arrest at G1/S phase.